

Attorney Docket No. P32969

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Bromidge et al. July 23, 2008
Serial No.: 10/501,317 Group Art Unit No.: 1625
Filed: February 22, 2005 Examiner: B. M. Robinson
For: Cyclic Urea Derivatives with 5-HT_{2C} Receptor Activity

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\DMF\Cases\P32969\RCE\Supp_IDS_Ltr.doc